

# Herman F Staats

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7678646/publications.pdf>

Version: 2024-02-01

89  
papers

4,289  
citations

126907

33  
h-index

114465

63  
g-index

91  
all docs

91  
docs citations

91  
times ranked

5019  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies. <i>Science</i> , 2005, 308, 1906-1908.	12.6	704
2	Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. <i>Nature Immunology</i> , 2003, 4, 1199-1205.	14.5	290
3	Mucosal immunity to infection with implications for vaccine development. <i>Current Opinion in Immunology</i> , 1994, 6, 572-583.	5.5	194
4	Mast cell activators: a new class of highly effective vaccine adjuvants. <i>Nature Medicine</i> , 2008, 14, 536-541.	30.7	192
5	Mast cell-derived particles deliver peripheral signals to remote lymph nodes. <i>Journal of Experimental Medicine</i> , 2009, 206, 2455-2467.	8.5	151
6	Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. <i>Vaccine</i> , 1994, 12, 903-911.	3.8	117
7	Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. <i>AAPS PharmSciTech</i> , 2007, 8, 2-10.	3.3	114
8	Mast Cells Augment Adaptive Immunity by Orchestrating Dendritic Cell Trafficking through Infected Tissues. <i>Cell Host and Microbe</i> , 2009, 6, 331-342.	11.0	113
9	Intranasal Immunization Is Superior to Vaginal, Gastric, or Rectal Immunization for the Induction of Systemic and Mucosal Anti-HIV Antibody Responses. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 945-952.	1.1	102
10	Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. <i>Scientific Reports</i> , 2014, 4, 5128.	3.3	94
11	Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization. <i>Journal of Virology</i> , 2002, 76, 517-524.	3.4	91
12	Cytokine Requirements for Induction of Systemic and Mucosal CTL After Nasal Immunization. <i>Journal of Immunology</i> , 2001, 167, 5386-5394.	0.8	90
13	Mucosal and systemic adjuvant activity of alphavirus replicon particles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 3722-3727.	7.1	90
14	Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. <i>Nature Materials</i> , 2012, 11, 250-257.	27.5	89
15	Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1159-1162.	2.9	89
16	Human Nasopharyngeal-Associated Lymphoreticular Tissues. <i>American Journal of Pathology</i> , 2000, 157, 2023-2035.	3.8	85
17	Stable Dry Powder Formulation for Nasal Delivery of Anthrax Vaccine. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 31-47.	3.3	82
18	MRGPR-mediated activation of local mast cells clears cutaneous bacterial infection and protects against reinfection. <i>Science Advances</i> , 2019, 5, eaav0216.	10.3	78

#	ARTICLE	IF	CITATIONS
19	Detection of Mucosal Antibodies in HIV Type 1-Infected Individuals. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 1291-1300.	1.1	72
20	The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with <i>Bacillus anthracis</i> protective antigen. <i>Vaccine</i> , 2009, 27, 3544-3552.	3.8	72
21	Prolonged CD4+Cell/Virus Load Discordance during Treatment with Protease Inhibitor-Based Highly Active Antiretroviral Therapy: Immune Response and Viral Control. <i>Journal of Infectious Diseases</i> , 2003, 187, 1027-1037.	4.0	71
22	A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. <i>Vaccine</i> , 2004, 22, 3774-3788.	3.8	58
23	Intranasal Immunization with Cytotoxic T-Lymphocyte Epitope Peptide and Mucosal Adjuvant Cholera Toxin: Selective Augmentation of Peptide-Presenting Dendritic Cells in Nasal Mucosa-Associated Lymphoid Tissue. <i>Infection and Immunity</i> , 1998, 66, 5876-5881.	2.2	58
24	Perivascular dendritic cells elicit anaphylaxis by relaying allergens to mast cells via microvesicles. <i>Science</i> , 2018, 362, .	12.6	56
25	In Vitro and In Vivo Characterization of Anthrax Anti-Protective Antigen and Anti-Lethal Factor Monoclonal Antibodies after Passive Transfer in a Mouse Lethal Toxin Challenge Model To Define Correlates of Immunity. <i>Infection and Immunity</i> , 2007, 75, 5443-5452.	2.2	55
26	Cytokines: The Future of Intranasal Vaccine Adjuvants. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-17.	3.3	52
27	<i>Salmonella</i> Typhimurium Impedes Innate Immunity with a Mast-Cell-Suppressing Protein Tyrosine Phosphatase, SptP. <i>Immunity</i> , 2013, 39, 1108-1120.	14.3	52
28	Scarcity or Absence of Humoral Immune Responses in the Plasma and Cervicovaginal Lavage Fluids of Heavily HIV-1-Exposed But Persistently Seronegative Women. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 469-486.	1.1	46
29	A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses. <i>Peptides</i> , 2013, 48, 96-105.	2.4	46
30	Mucosal Immunization of Lactating Female Rhesus Monkeys with a Transmitted/Founder HIV-1 Envelope Induces Strong Env-Specific IgA Antibody Responses in Breast Milk. <i>Journal of Virology</i> , 2013, 87, 6986-6999.	3.4	38
31	Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. <i>Journal of Virology</i> , 2019, 93, .	3.4	37
32	Mucosal Targeting of a BoNT/A Subunit Vaccine Adjuvanted with a Mast Cell Activator Enhances Induction of BoNT/A Neutralizing Antibodies in Rabbits. <i>PLoS ONE</i> , 2011, 6, e16532.	2.5	36
33	Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1. <i>Vaccine</i> , 2010, 28, 6901-6914.	3.8	34
34	Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. <i>Vaccine</i> , 2008, 26, 4267-4275.	3.8	33
35	A Novel Neurotoxoid Vaccine Prevents Mucosal Botulism. <i>Journal of Immunology</i> , 2005, 174, 2190-2195.	0.8	32
36	An Entirely Cell-Based System to Generate Single-Chain Antibodies against Cell Surface Receptors. <i>Journal of Molecular Biology</i> , 2008, 379, 261-272.	4.2	30

#	ARTICLE	IF	CITATIONS
37	A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen. <i>Vaccine</i> , 2013, 31, 1480-1489.	3.8	27
38	Mucosal Vaccine Targeting Improves Onset of Mucosal and Systemic Immunity to Botulinum Neurotoxin A. <i>Journal of Immunology</i> , 2006, 177, 5524-5532.	0.8	26
39	Nonmucosal Alphavirus Vaccination Stimulates a Mucosal Inductive Environment in the Peripheral Draining Lymph Node. <i>Journal of Immunology</i> , 2008, 181, 574-585.	0.8	25
40	Maximal Adjuvant Activity of Nasally Delivered IL-1 $\beta$ Requires Adjuvant-Responsive CD11c+ Cells and Does Not Correlate with Adjuvant-Induced In Vivo Cytokine Production. <i>Journal of Immunology</i> , 2012, 188, 2834-2846.	0.8	23
41	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. <i>Journal of Virology</i> , 2016, 90, 4951-4965.	3.4	23
42	Mast cell activators as novel immune regulators. <i>Current Opinion in Pharmacology</i> , 2018, 41, 89-95.	3.5	23
43	Oral immunogenicity of the plant proteinase bromelain. <i>International Immunopharmacology</i> , 2006, 6, 2038-2046.	3.8	22
44	Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination. <i>Vaccine</i> , 2015, 33, 3609-3613.	3.8	22
45	Effective Antibody Therapy in Herpes Simplex Virus Ocular Infection. <i>Intervirology</i> , 1990, 31, 159-165.	2.8	21
46	The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. <i>Vaccine</i> , 2008, 26, 4998-5003.	3.8	21
47	Immunization with the <i>Haemophilus ducreyi</i> Hemoglobin Receptor HgbA with Adjuvant Monophosphoryl Lipid A Protects Swine from a Homologous but Not a Heterologous Challenge. <i>Infection and Immunity</i> , 2010, 78, 3763-3772.	2.2	21
48	Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy. <i>Npj Vaccines</i> , 2020, 5, 12.	6.0	21
49	Generation of Mucosal Anti-Human Immunodeficiency Virus Type 1 T-Cell Responses by Recombinant <i>Mycobacterium smegmatis</i> . <i>Vaccine Journal</i> , 2006, 13, 1204-1211.	3.1	20
50	Fecal IgA, Antigen Absorption, and Gut Microbiome Composition Are Associated With Food Antigen Sensitization in Genetically Susceptible Mice. <i>Frontiers in Immunology</i> , 2020, 11, 599637.	4.8	20
51	Increased immunogenicity of HIV envelope subunit complexed with $\beta$ 2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF. <i>Vaccine</i> , 2002, 20, 2396-2403.	3.8	18
52	Evaluation of vaccine-induced antibody responses: Impact of new technologies. <i>Vaccine</i> , 2013, 31, 2756-2761.	3.8	18
53	The V3 Domain of SIVmac251 gp120 Contains a Linear Neutralizing Epitope. <i>Virology</i> , 1996, 224, 415-426.	2.4	17
54	Gender Differences in Human Immunodeficiency Virus Type 1-Specific CD8 Responses in the Reproductive Tract and Colon following Nasal Peptide Priming and Modified Vaccinia Virus Ankara Boosting. <i>Journal of Virology</i> , 2004, 78, 13163-13172.	3.4	17

#	ARTICLE	IF	CITATIONS
55	Capric Acid and Hydroxypropylmethylcellulose Increase the Immunogenicity of Nasally Administered Peptide Vaccines. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 558-568.	1.1	16
56	Application of Basic Principles of Mucosal Immunity to Vaccine Development. , 1996, , 17-39.		16
57	Dry Powder Vaccines for Mucosal Administration: Critical Factors in Manufacture and Delivery. <i>Current Topics in Microbiology and Immunology</i> , 2011, 354, 121-156.	1.1	15
58	A mast cell degranulation screening assay for the identification of novel mast cell activating agents. <i>MedChemComm</i> , 2013, 4, 88-94.	3.4	15
59	Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8+ T cell population in different tissues. <i>Vaccine</i> , 2004, 22, 1390-1394.	3.8	14
60	Mucosal vaccine development for botulinum intoxication. <i>Expert Review of Vaccines</i> , 2007, 6, 35-45.	4.4	13
61	Genetic determinants of immune-response to a polysaccharide vaccine for typhoid. <i>The HUGO Journal</i> , 2009, 3, 17-30.	4.1	13
62	Immunization with the <i>Haemophilus ducreyi</i> trimeric autotransporter adhesin DsrA with alum, CpG or imiquimod generates a persistent humoral immune response that recognizes the bacterial surface. <i>Vaccine</i> , 2016, 34, 1193-1200.	3.8	12
63	Nasal peanut+ CpG immunotherapy enhances peanut-specific IFN $\gamma$ in Th2 cells and IL10 in non-Th2 cells in mice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2220-2223.	5.7	12
64	Serological response following re-vaccination with <i>Salmonella typhi</i> Vi-capsular polysaccharide vaccines in healthy adult travellers. <i>Vaccine</i> , 2015, 33, 4141-4145.	3.8	11
65	Development of a Bead Immunoassay To Measure Vi Polysaccharide-Specific Serum IgG after Vaccination with the <i>Salmonella enterica</i> Serovar Typhi Vi Polysaccharide. <i>Vaccine Journal</i> , 2010, 17, 412-419.	3.1	10
66	Adjuvanted Immunotherapy Approaches for Peanut Allergy. <i>Frontiers in Immunology</i> , 2018, 9, 2156.	4.8	10
67	Chaperoning vaccines. <i>Nature Materials</i> , 2010, 9, 537-538.	27.5	9
68	Genomic correlates of variability in immune response to an oral cholera vaccine. <i>European Journal of Human Genetics</i> , 2013, 21, 1000-1006.	2.8	9
69	Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen. <i>Journal of Virology</i> , 2019, 93, .	3.4	9
70	Nasal Immunization With Small Molecule Mast Cell Activators Enhance Immunity to Co-Administered Subunit Immunogens. <i>Frontiers in Immunology</i> , 2021, 12, 730346.	4.8	9
71	Adenovirus F protein as a delivery vehicle for botulinum B. <i>BMC Immunology</i> , 2010, 11, 36.	2.2	7
72	Assessing the satisfaction and burden within an academic animal care and use program. <i>FASEB Journal</i> , 2017, 31, 3913-3921.	0.5	7

#	ARTICLE	IF	CITATIONS
73	Identification of Novel Mast Cell Activators Using Cell-Based High-Throughput Screening. <i>SLAS Discovery</i> , 2019, 24, 628-640.	2.7	7
74	Highly-loaded protein nanocarriers prepared by Flash NanoPrecipitation with hydrophobic ion pairing. <i>International Journal of Pharmaceutics</i> , 2021, 601, 120397.	5.2	7
75	Identification of recombinant antibodies against multiple distinct toll-like receptors by homolog mining a single immune scFv phage library. <i>Journal of Immunological Methods</i> , 2009, 340, 144-153.	1.4	6
76	Effect of endotoxin and alum adjuvant vaccine on peanut allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 791-794.e8.	2.9	6
77	Innate Immunity-Based Mucosal Modulators and Adjuvants. , 2020, , 167-183.		5
78	Scale of Health: Indices of Safety and Efficacy in the Evolving Environment of Large Biological Datasets. <i>Pharmaceutical Research</i> , 2014, 31, 2256-2265.	3.5	4
79	Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge. <i>Vaccine Journal</i> , 2016, 23, 648-651.	3.1	4
80	Vaccines for Selective Induction of Th1- and Th2-Cell Responses and Their Roles in Mucosal Immunity. , 1996, , 461-475.		4
81	Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. <i>Journal of Controlled Release</i> , 2015, 213, e66-e67.	9.9	2
82	Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits ( <i>Oryctolagus cuniculus</i> ). <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	2
83	Mucosal Immunity in HIV Infection. , 1996, , 387-416.		2
84	Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxin. <i>Immunopharmacology</i> , 1995, 31, 31-41.	2.0	1
85	Nasal Dry Powder Vaccine Delivery Technology. , 2014, , 717-726.		1
86	Mast Cells for the Control of Mucosal Immunity. , 2020, , 213-228.		1
87	Which comes first: the antigen or the adjuvant?. <i>Journal of Clinical Investigation</i> , 2014, 124, 2364-2365.	8.2	1
88	HIV Vaccine Development at Duke University Medical Center. <i>Immunologic Research</i> , 2000, 22, 263-270.	2.9	0
89	HIV Mucosal Vaccines. , 2002, , 165-190.		0